Large Outflow of Money Witnessed in Sanofi

Sanofi (SNY) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (1.57 million) in Sanofi (SNY). On Friday, The value of composite uptick trades was $1.01 million, whereas, the value of composite downtick trades was $2.58 million and the ratio between the two was 0.39, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $1.34 million. The negative money flow of ($1.34 million) shows selling on strength. Sanofi (SNY) gained $0.72 intraday at $39.13 and registrered 1.87% for the week.


The company Insiders own 1% of Sanofi shares according to the proxy statements. Institutional Investors own 9.42% of Sanofi shares.

Sanofi (NYSE:SNY): The stock opened at $39.27 and touched an intraday high of $39.2999 on Friday. During the day, the stock corrected to an intraday low of $39.02, however, the bulls stepped in and pushed the price higher to close in the green at $39.18 with a gain of 2.00% for the day. The total traded volume for the day was 1,306,073. The stock had closed at $38.41 in the previous trading session.

Sanofi (SNY) has been under a strong bear grip, hence the stock is down -2.7% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.5% in the past 1 week. The stock has risen by 1.01% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.83% in the past 4 weeks.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *